Allogeneic Anti-CD19/CD22 CAR-BBz T-cells

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of allogeneic T-lymphocytes that have been transduced with a bivalent lentiviral vector encoding a chimeric antigen receptor (CAR) targeting the two tumor-associated antigens (TAAs) CD19 and CD22, linked to the co-stimulatory domain 4-1BB (CD137) coupled to the zeta chain of the TCR/CD3 complex (TCRzeta; CD247; CD3zeta), with potential immunostimulating and antineoplastic activities. Upon administration, the allogeneic anti-CD19/CD22 CAR-BBz T-cells bind to and induce selective toxicity in tumor cells expressing CD19 and CD22. CD19 and CD22, both transmembrane phosphoglycoproteins expressed on the surface of cells in the B lineage, are often overexpressed on malignant B-cells. By simultaneously targeting two B-cell antigens, this preparation may minimize relapse due to single antigen loss in patients with B-cell malignancies.

**Synonyms:** - Allogeneic Anti-CD19/Anti-CD22 CAR T Cells - Allogeneic Anti-CD19/CD22 CAR T-cells - Allogeneic Anti-CD19/CD22 CAR-T Cells - Allogeneic CD19/CD22-BBz CAR T Cells - Allogeneic CD19/CD22-CAR T Cells